J&J/Merck says Pepcid AC onset of action is comparable to Tagamet HB in Sept. 5 suit.
This article was originally published in The Tan Sheet
Executive Summary
PEPCID AC ONSET OF ACTION COMPARABLE TO TAGAMET HB, J&J/MERCK ARGUES in a complaint filed Sept. 5 in District Court for the Southern District of New York. Based on "several" head-to-head comparisons between the two H2 antagonists, Johnson & Johnson/Merck maintained that "Pepcid AC and Tagamet HB have repeatedly been shown to work at the same rate of speed." J&J/Merck said it has conducted comparative assessments of the products in both acid control and symptom relief.